Table 1 Response rates and duration of response in patients treated with venetoclax + azacitidine or azacitidine alone.
Response parameter | Venetoclax + azacitidine | Azacitidine | ||||
|---|---|---|---|---|---|---|
All secondary AML (N = 90) | tAML (n = 31) | A-MDS/CMML (n = 59) | All secondary AML (N = 35) | tAML (n = 9) | A-MDS/CMML (n = 26) | |
CR + CRi, n (%) (95% CI) | 58 (64.4) (53.7–74.3) | 19 (61.3) (42.2–78.2) | 39 (66.1) (52.6–77.9) | 9 (25.7) (12.5–43.3) | 1 (11.0) (0.3–48.2) | 8 (30.8) (14.3–51.8) |
CR, n (%) | 31 (34.4) | 10 (32.3) | 21 (35.6) | 4 (11.4) | 1 (11.1) | 3 (11.5) |
CRi, n (%) | 27 (30.0) | 9 (29.0) | 18 (30.5) | 5 (14.3) | 0 | 5 (19.2) |
Median duration of CR/CRi, months (95% CI) | 21.0 (15.7–25.5) | 25.5 (17.8–NE) | 17.3 (9.6–25.1) | 5.8 (1.0–15.6) | 8.5 (NE) | 5.8 (1.0–NE) |
